Acurx Pharmaceuticals (ACXP) Earnings Analysis
Acurx Pharmaceuticals (ACXP) next reports earnings on 2026-08-14, consensus EPS -0.42 USD. Last quarter (2026-03-13) it beat with EPS -0.31 USD vs -1.01 USD est (+69.3%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E -0.30.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ACXP next report earnings?
| Next earnings date | 2026-08-14 |
|---|---|
| Consensus EPS estimate | -0.42 USD |
| Revenue estimate | n/a |
ACXP earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-13 | -0.31 USD | -1.01 USD | +69.3% | Beat |
| 2025-11-12 | -1.23 USD | -1.61 USD | +23.6% | Beat |
| 2025-08-11 | -1.89 USD | -2 USD | +5.5% | Beat |
| 2025-05-12 | -2.2 USD | -0.15 USD | -1366.7% | Miss |
| 2025-03-17 | -0.16 USD | -0.18 USD | +11.1% | Beat |
| 2024-08-09 | -0.26 USD | -0.28 USD | +7.1% | Beat |
Beat rate: 5/6 (83%) over reported quarters with consensus data.
ACXP valuation and analyst view
| Trailing P/E | -0.30 |
|---|---|
| Trailing EPS | -5.00222 USD |
| Price / book | 0.31 |
| Dividend yield | 0.00% |
| Market cap | 0.00B |
| Analyst consensus | Buy (3 buy / 0 hold / 0 sell) |
Related research pages
Frequently asked questions
When is Acurx Pharmaceuticals (ACXP)'s next earnings date?
Acurx Pharmaceuticals is next scheduled to report on 2026-08-14, with a consensus EPS estimate of -0.42 USD.
Did ACXP beat earnings last quarter?
In its 2026-03-13 report, ACXP posted EPS of -0.31 USD versus a -1.01 USD estimate — a beat of 69.3%.
What is ACXP's earnings track record?
Over the last 6 reported quarters with consensus data, ACXP beat estimates 5 times (83%).
What is ACXP's current P/E ratio and EPS?
ACXP trades at a trailing P/E of -0.30 on trailing EPS of -5.002219479653102 USD.
What do analysts rate ACXP?
Analyst consensus is "Buy" across 3 ratings (0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell).